Table 1.
Patient Characteristics.
Table 2.
Histological type of STS.
Fig 1.
Immunohistochemical detection of GATA3 expression in soft tissue sarcomas (Original magnification, x400; insert, x600).
GATA3 was present in the nuclei of STS cells at various proportions. (A) An undifferentiated/unclassified sarcomas case with 30% GATA3 expression. (B) A leiomyosarcoma case with 80% GATA3 expression. (C) A malignant peripheral nerve sheath tumor case with 70% GATA3 expression. (D) A myxoid liposarcoma case with 7% GATA3 expression.
Fig 2.
The distribution of GATA3 positive rate in soft tissue sarcomas.
(A) The histogram of the GATA3 positive rate shows skewed distribution in all cases. (B) The histogram of GATA3 which focuses the percentage from 0 to 10 with the longitudinal axis by every 1 percent.
Table 3.
Statistical association between clinical characteristics and GATA3 expression.
Fig 3.
Comparison of disease-free survival curves between GATA3-positive (continuous line) and -negative (dotted line) STS cases.
(A) Among all STS cases, GATA3-positive cases experienced significantly worse DFS compared to GATA3-negative cases (P = 0.0104). (B) Among FNCLCC histological grade 1 cases, no significant differences were observed between GATA-3 positive and -negative cases. (C) Among FNCLCC histological grade 2/3 cases, GATA3-positive cases experienced significantly worse DFS compared to GATA3-negative cases (P = 0.0160). (D) Among cases with tumors ≤ 5 cm, no significant differences were observed between GATA-3 positive and -negative cases. (E) Among cases with tumors > 5 cm, GATA3-positive cases experienced significantly worse DFS compared to GATA3-negative cases (P = 0.0256).
Fig 4.
Comparison of overall survival curves between GATA3-positive (continuous line) and -negative (dotted line) cases.
(A) Among all STS cases, OS for GATA3-positive cases was significantly worse than that for GATA3-negative cases (P = 0.0006). (B) Among FNCLCC histological grade 1 and (C) FNCLCC histological grade 2/3 cases, GATA3-positive cases experienced significantly worse OS compared to GATA3-negative cases (P = 0.0455 and P = 0.0047, respectively). (D) Among cases with tumors ≤ 5 cm, no significant differences were observed between GATA-3 positive and -negative cases. (E) Among cases with tumors > 5 cm, GATA3-positive cases experienced significantly worse OS compared to GATA3-negative cases (P = 0.0040).
Table 4.
Univariate and multivariate Cox regression analysis for disease-free survival in STS patients.
Table 5.
Univariate and multivariate Cox regression analysis for overall survival in STS patients.